Invega Sustenna (paliperidone palmitate) is a prescription drug that’s used to treat schizophrenia and schizoaffective disorder. Invega Sustenna is given as an injection into your muscle by a ...

Janssen announced submission of a supplemental New Drug Application (sNDA) to the FDA for a label change to include new data demonstrating significantly delayed time to relapse in patients taking ...

The "Drug Overview: Invega Sustenna/Invega Trinza" report has been added to ResearchAndMarkets.com's offering. Invega Sustenna and Invega Trinza (paliperidone palmitate; Johnson & Johnson) are ...

TITUSVILLE, N.J., May 24 /PRNewswire/ --New data on INVEGA® SUSTENNA® (paliperidone palmitate), a long-acting injectable medicine for schizophrenia, and new data on RISPERDAL® CONSTA® (risperidone ...

Janssen announced positive results of its PRIDE (Paliperidone Palmitate Research In Demonstrating Effectiveness) trial that compared schizophrenia medications. Results showed that once-monthly Invega ...

After incurring a loss in New Jersey federal court in 2021, Teva and Viatris have successfully resurrected challenges to the last remaining U.S. patent on a lucrative Johnson & Johnson schizophrenia ...

Johnson & Johnson JNJ suffered a setback when the FDA issued a complete response letter (CRL) in response to the company’s supplemental new drug application (sNDA) for the once-monthly long-acting ...

(Reuters) -Teva Pharmaceutical and Viatris convinced a U.S. appeals court on Monday to revive their challenges to a patent covering a blockbuster Johnson & Johnson schizophrenia drug, giving them a ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. INVEGA SUSTENNA contains the active ingredient paliperidone palmitate.